José Luna-Muñoz Selected Research

José Luna-Muñoz Research Topics

14	Alzheimer Disease (Alzheimer's Disease) 05/2022 - 09/2005
4	Neurodegenerative Diseases (Neurodegenerative Disease) 09/2022 - 01/2020
3	Parkinson Disease (Parkinson's Disease) 09/2022 - 01/2021
3	Amyloid Plaque 01/2022 - 01/2016
2	Neuroinflammatory Diseases 02/2023 - 10/2021
2	Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome) 01/2021 - 01/2021
2	Tauopathies 01/2021 - 01/2020
1	Mitochondrial Diseases (Mitochondrial Disease) 02/2023
1	Synucleinopathies 09/2022
1	Cerebral Amyloid Angiopathy (Congophilic Angiopathy) 02/2021
1	Brain Diseases (Brain Disorder) 01/2021
1	COVID-19 01/2021
1	Memory Disorders (Memory Loss) 01/2021
1	Prion Diseases (Transmissible Spongiform Encephalopathies) 01/2021
1	Frontotemporal Dementia (Semantic Dementia) 01/2021
1	Cognitive Dysfunction 01/2021
1	Pathologic Processes 01/2020
1	Neuroblastoma 01/2019
1	Inflammation (Inflammations) 01/2014
1	Gliosis 01/2014
1	Down Syndrome (Down's Syndrome) 01/2014
1	Infections 09/2008

9	tau Proteins (tau Protein)IBA 02/2023 - 09/2005
6	Amyloid (Amyloid Fibrils)IBA 01/2022 - 01/2014
5	Peptides (Polypeptides)IBA 02/2023 - 01/2014
5	Proteins (Proteins, Gene)FDA Link 10/2021 - 09/2008
3	Amyloid beta-PeptidesIBA 02/2023 - 11/2008
3	Biomarkers (Surrogate Marker)IBA 09/2022 - 01/2020
2	PrionsIBA 09/2022 - 01/2021
2	SynucleinsIBA 09/2022 - 10/2021
1	gamma-sitosterol (beta-sitosterol)IBA 09/2022
1	GlucosidesIBA 09/2022
1	Glial Cell Line-Derived Neurotrophic Factor (GDNF)IBA 10/2021
1	AngiotensinsIBA 01/2021
1	Glial Fibrillary Acidic ProteinIBA 01/2021
1	Matrix Metalloproteinases (MMPs)IBA 01/2021
1	AntibodiesIBA 01/2020
1	CopperIBA 01/2014
1	CholesterolIBA 01/2014
1	Acetylcholine (Acetylcholine Chloride)FDA Link 01/2014
1	Pyrrolidonecarboxylic Acid (Pyroglutamic Acid)IBA 01/2014
1	theasinensin AIBA 03/2013
1	thiazin redIBA 11/2008
1	Coloring Agents (Dyes)IBA 11/2008
1	Profilins (Profilin)IBA 09/2008
1	Wiskott-Aldrich Syndrome ProteinIBA 09/2008
1	EpitopesIBA 12/2007
1	PolymersIBA 12/2007

2	Therapeutics 10/2021 - 01/2021